Tcr2 Therapeutics Ownership
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Tcr2 |
Tcr2 Stock Ownership Analysis
About 54.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.22. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tcr2 Therapeutics recorded a loss per share of 4.2. The entity had not issued any dividends in recent years. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Tcr2 Therapeutics contact Dr MBA at 617 949 5200 or learn more at https://www.tcr2.com.Tcr2 Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tcr2 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tcr2 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tcr2 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mpm Sunstates Fund Lp over a year ago Acquisition or disposition of Tcr2 Therapeutics securities by Mpm Sunstates Fund Lp | ||
Peter Olagunju over a year ago Disposition of 24092 shares by Peter Olagunju of Tcr2 Therapeutics subject to Rule 16b-3 | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 50000 shares of Tcr2 Therapeutics | ||
Mpm Asset Management Llc over a year ago Exercise of in-the-money or at-the-money derivative position by Mpm Asset Management Llc of 135508 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 38765 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 57073 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Tcr2 Therapeutics exotic insider transaction detected |
Tcr2 Therapeutics Outstanding Bonds
Tcr2 Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tcr2 Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tcr2 bonds can be classified according to their maturity, which is the date when Tcr2 Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US878091BD86 Corp BondUS878091BD86 | View | |
| US878091BG18 Corp BondUS878091BG18 | View | |
| US878091BF35 Corp BondUS878091BF35 | View | |
| US878091BC04 Corp BondUS878091BC04 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Pair Trading with Tcr2 Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Tcr2 Stock
| 0.86 | EC | Ecopetrol SA ADR | PairCorr |
| 0.68 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.67 | SHG | Shinhan Financial | PairCorr |
| 0.59 | WF | Woori Financial Group | PairCorr |
| 0.56 | TLK | Telkom Indonesia Tbk | PairCorr |
The ability to find closely correlated positions to Tcr2 Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tcr2 Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tcr2 Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tcr2 Therapeutics to buy it.
The correlation of Tcr2 Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tcr2 Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tcr2 Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tcr2 Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |